REGN
Regeneron Pharmaceuticals, Inc.
NasdaqGSUSDEQUITY
Healthcare
DELAYED
Neutral
-1/100
Last price
734.00
▲ 7.06 (0.97%)
MARKET · —
Price
Chart style
Interval
Intraday intervals only cover recent history. The site picks the finest interval the range allows.
Overlays
Session levels
Lower pane
Overlay another symbol
Both series are rebased to 0% at the left edge, so the lines show relative performance rather than price.
Tool
1D
—
H —
L —
Range —
Vol —
vs
Drag pan · Pinch zoom · Hold crosshair · pick a tool then drag to draw
Open
726.47
Prev close
726.94
Day high
740.51
Day low
727.16
Volume
615.06K
Market cap
$76.05B
P/E (TTM)
17.96
52W range
541.00 – 859.34
Day trading desk
Gap from prior close
+0.00%
Prior close 726.47
VWAP
737.02
-0.41% from price
Relative volume
1.32×
Normal
Session range
2.78%
721.96 – 742.03
Position in range
60%
Mid range
ATR (14D)
21.14
2.88% of price
Prior day high
736.42
PDH
Prior day low
722.02
PDL
Bid / ask spread
—
Quote not published
Session volume
981.38K
Avg 741.55K
VWAP and the session figures are computed from the delayed intraday series on this page, so they lag the live tape and will not match a broker's real-time VWAP exactly. Turn on Prior day H/L/C, Opening range and Volume profile in the chart's Studies menu to see these levels drawn on price.
Trailing performance
Returnvs SPY
1W
-1.57%
-3.5%
1M
-10.75%
-11.9%
3M
+11.44%
+6.9%
6M
-2.83%
-21.0%
YTD
-4.29%
-18.5%
1Y
+23.12%
+6.7%
3Y
-10.24%
-92.5%
5Y
—
—
Price return only. Dividends are not reinvested, so total return on a dividend payer will be higher than shown.
Unusual options activity
Nothing crossed the thresholds in the expiries we scanned.
That is the normal state — most contracts trade well inside their existing open interest.
That is the normal state — most contracts trade well inside their existing open interest.
Contracts trading at or above their open interest, ranked by notional and where the print landed.
Free account
5 more panels on REGN open with an account.
Options chains and analytics, valuation ratios, insider filings, analyst targets and ownership. No card, no trial, nothing to cancel.
Insider net activity
Net shares
+15.92K
Net buying
Buy transactions
5
20.16K shares
Sell transactions
6
4.25K shares
Net transactions
+11
Buys less sells
Sell : buy shares
0.2 : 1
Mixed
Insider-held shares
2.08M
Total on file
Insider transactions
| Date | Insider | Action | Shares | Value | Held |
|---|---|---|---|---|---|
| Sep 3, 26 | MCCOURT MARION E Officer |
SELL | 2.35K | $2.00M | Direct |
| Sep 2, 26 | GUARINI KATHRYN PH.D. Director |
CONVERSION | 400 | $287.75K | Direct |
| Sep 2, 26 | GUARINI KATHRYN PH.D. Director |
SELL | 400 | $340.00K | Direct |
| Aug 19, 26 | LAROSA JOSEPH J General Counsel |
CONVERSION | 12.28K | $4.69M | Direct |
| Aug 18, 26 | FENIMORE CHRISTOPHER R Chief Financial Officer |
CONVERSION | 6.28K | $2.40M | Direct |
| Aug 10, 26 | GUARINI KATHRYN PH.D. Director |
CONVERSION | 400 | $287.75K | Direct |
| Aug 10, 26 | ZOGHBI HUDA Y Director |
CONVERSION | 800 | $301.35K | Direct |
| Aug 10, 26 | GUARINI KATHRYN PH.D. Director |
SELL | 400 | $320.00K | Direct |
| Aug 10, 26 | ZOGHBI HUDA Y Director |
SELL | 800 | $640.00K | Direct |
| Jul 2, 26 | RYAN ARTHUR F. Director |
SELL | 200 | $130.03K | Direct |
| May 1, 26 | RYAN ARTHUR F. Director |
SELL | 100 | $70.52K | Direct |
| Apr 1, 26 | RYAN ARTHUR F. Director |
SELL | 100 | $77.73K | Direct |
| Mar 2, 26 | RYAN ARTHUR F. Director |
SELL | 100 | $78.55K | Direct |
| Feb 19, 26 | ZOGHBI HUDA Y Director |
CONVERSION | 1.64K | $617.02K | Direct |
What this is, and what it is not
These are SEC Form 4 filings — officers, directors and 10% owners reporting their own trades in the company's stock. Filing is due within two business days of the transaction, so this lags reality by days, and the provider adds its own lag on top.
A sale is not automatically bearish. Executives sell on scheduled 10b5-1 plans, to cover tax on vesting equity, and to diversify. Purchases with cash are generally the more informative signal, and they are far rarer.
This does not include congressional or senate trading. That comes from STOCK Act disclosures filed with the Senate eFD system and the House Clerk, which this data source does not carry.
Officer and director trades in their own stock, straight from Form 4 filings.
Insider holders
| Name | Relation | Shares held | Latest |
|---|---|---|---|
BROWN MICHAEL S |
Director | 12.87K | Stock Award(Grant) |
FENIMORE CHRISTOPHER R |
Chief Financial Officer | 23.50K | Conversion of Exercise of derivative security |
LAROSA JOSEPH J |
General Counsel | 45.59K | Conversion of Exercise of derivative security |
MCCOURT MARION E |
Officer | 15.57K | Stock Award(Grant) |
MURPHY ANDREW J |
Officer | 56.44K | Stock Award(Grant) |
RYAN ARTHUR F. |
Director | 17.30K | Sale |
SCHLEIFER LEONARD S |
Chief Executive Officer | 687.98K | Conversion of Exercise of derivative security |
SING GEORGE LOUIS |
Director | 33.16K | Stock Award(Grant) |
VAN PLEW DANIEL P |
Officer | 37.73K | Stock Award(Grant) |
YANCOPOULOS GEORGE D |
President | 1.13M | Conversion of Exercise of derivative security |
Fundamentals
Market cap$76.05B
Enterprise value$68.48B
Revenue (TTM)$15.53B
Gross profit$6.91B
EBITDA$4.70B
Net income$4.33B
EPS (TTM)$41.12
Free cash flow$3.07B
Total cash$7.99B
Total debt$2.71B
Book value / share$316.11
Shares outstanding101.14M
Float95.85M
Short % of float2.60%
Dividend yield0.52%
Beta (5Y)0.15
Valuation & profitability ratios
Trailing P/E17.96
Forward P/E12.02
PEG ratio1.24
Price / sales—
Price / book2.34
EV / revenue4.41
EV / EBITDA14.56
Gross margin44.46%
Operating margin33.11%
Profit margin27.87%
Return on equity14.04%
Return on assets6.53%
Debt / equity8.54
Current ratio3.34
Fourteen ratios including P/E, PEG, EV/EBITDA, margins and return on equity.
Financial statements
| Line item | 2025 | 2024 | 2023 | 2022 | YoY |
|---|---|---|---|---|---|
| Total revenue | $14.34B | $14.20B | $13.12B | $12.17B | +1.0% |
| Operating revenue | $13.64B | $13.69B | $12.58B | $11.81B | -0.3% |
| Cost of revenue | $2.10B | $1.97B | $1.82B | $1.56B | +6.6% |
| Gross profit | $12.24B | $12.23B | $11.30B | $10.61B | +0.1% |
| Research & development | $5.85B | $5.23B | $4.63B | $3.85B | +11.8% |
| Selling, general & admin | $2.70B | $2.95B | $2.63B | $2.12B | -8.6% |
| Total operating expense | $8.54B | $8.24B | $7.25B | $5.87B | +3.6% |
| Operating income | $3.70B | $3.99B | $4.05B | $4.74B | -7.2% |
| Net interest income | $673.00M | $656.20M | $422.90M | $100.70M | +2.6% |
| Pre-tax income | $5.23B | $4.78B | $4.20B | $4.86B | +9.4% |
| Tax provision | $725.80M | $367.30M | $245.70M | $520.40M | +97.6% |
| Net income | $4.50B | $4.41B | $3.95B | $4.34B | +2.1% |
| Net income to common | $4.50B | $4.41B | $3.95B | $4.34B | +2.1% |
| Basic EPS | 43.07 | 40.90 | 37.05 | 40.51 | +5.3% |
| Diluted EPS | 41.48 | 38.34 | 34.77 | 38.22 | +8.2% |
| EBIT | $5.27B | $4.84B | $4.27B | $4.92B | +9.1% |
| EBITDA | $5.82B | $5.32B | $4.69B | $5.26B | +9.4% |
| Basic shares | 104.60M | 107.90M | 106.70M | 107.10M | -3.1% |
| Diluted shares | 108.60M | 115.10M | 113.70M | 113.50M | -5.6% |
| Line item | 2025 | 2024 | 2023 | 2022 | YoY |
|---|---|---|---|---|---|
| Cash & equivalents | $3.12B | $2.49B | $2.73B | $3.11B | +25.3% |
| Cash & short-term investments | $8.61B | $9.01B | $10.84B | $7.74B | -4.5% |
| Accounts receivable | $5.74B | $6.21B | $5.67B | $5.33B | -7.6% |
| Inventory | $3.20B | $3.09B | $2.58B | $2.40B | +3.7% |
| Total current assets | $18.02B | $18.66B | $19.48B | $15.88B | -3.4% |
| Property, plant & equipment | $5.12B | $4.60B | $4.15B | $3.76B | +11.3% |
| Goodwill & intangibles | $1.26B | $1.15B | $1.04B | $915.50M | +9.5% |
| Total assets | $40.56B | $37.76B | $33.08B | $29.21B | +7.4% |
| Total current liabilities | $4.37B | $3.94B | $3.42B | $3.14B | +10.8% |
| Long-term debt | $1.99B | $1.98B | $1.98B | $1.98B | +0.1% |
| Total debt | $2.71B | $2.70B | $2.70B | $2.70B | +0.1% |
| Total liabilities | $9.30B | $8.41B | $7.11B | $6.55B | +10.7% |
| Retained earnings | $35.80B | $31.67B | $27.26B | $23.31B | +13.0% |
| Shareholder equity | $31.26B | $29.35B | $25.97B | $22.66B | +6.5% |
| Working capital | $13.65B | $14.72B | $16.06B | $12.74B | -7.2% |
| Net tangible assets | $30.00B | $28.20B | $24.93B | $21.75B | +6.4% |
| Shares issued | 139.42M | 137.82M | 134.92M | 132.20M | +1.2% |
| Line item | 2025 | 2024 | 2023 | 2022 | YoY |
|---|---|---|---|---|---|
| Net income | $4.50B | $4.41B | $3.95B | $4.34B | +2.1% |
| Depreciation & amortisation | $543.70M | $482.90M | $421.00M | $341.40M | +12.6% |
| Stock-based compensation | $993.70M | $982.80M | $885.00M | $725.00M | +1.1% |
| Change in working capital | $532.60M | -$618.30M | -$94.10M | -$243.30M | +186.1% |
| Operating cash flow | $4.98B | $4.42B | $4.59B | $5.01B | +12.6% |
| Capital expenditure | -$1.21B | -$881.60M | -$926.40M | -$1.62B | -37.7% |
| Investing cash flow | -$629.10M | -$2.47B | -$3.19B | -$3.78B | +74.5% |
| Share buybacks | -$3.97B | -$3.63B | -$2.94B | -$2.53B | -9.3% |
| Dividends paid | -$370.30M | $0 | $0 | — | — |
| Financing cash flow | -$3.72B | -$2.20B | -$1.79B | -$1.01B | -68.8% |
| Free cash flow | $3.77B | $3.54B | $3.67B | $3.40B | +6.4% |
| End cash position | $3.12B | $2.49B | $2.74B | $3.12B | +25.5% |
| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | YoY |
|---|---|---|---|---|---|---|
| Total revenue | $4.29B | $3.61B | $3.88B | $3.75B | $3.68B | +19.0% |
| Operating revenue | $4.10B | $3.43B | $3.65B | $3.56B | $3.49B | +19.3% |
| Cost of revenue | $576.50M | $669.40M | $584.60M | $521.60M | $530.20M | -13.9% |
| Gross profit | $3.71B | $2.94B | $3.30B | $3.23B | $3.15B | +26.5% |
| Research & development | $1.63B | $1.54B | $1.63B | $1.48B | $1.43B | +5.7% |
| Selling, general & admin | $662.10M | $647.70M | $775.00M | $657.80M | $634.20M | +2.2% |
| Total operating expense | $2.29B | $2.19B | $2.40B | $2.12B | $2.07B | +4.7% |
| Operating income | $1.42B | $744.80M | $898.60M | $1.11B | $1.08B | +90.7% |
| Net interest income | $172.30M | $170.60M | $181.10M | $155.80M | $171.20M | +1.0% |
| Pre-tax income | $1.53B | $831.20M | $1.04B | $1.76B | $1.52B | +83.8% |
| Tax provision | $230.90M | $104.00M | $199.10M | $303.30M | $127.10M | +122.0% |
| Net income | $1.30B | $727.20M | $844.60M | $1.46B | $1.39B | +78.3% |
| Net income to common | $1.30B | $727.20M | $844.60M | $1.46B | $1.39B | +78.3% |
| Basic EPS | 12.62 | 6.99 | 8.21 | 14.09 | 13.24 | +80.5% |
| Diluted EPS | 12.23 | 6.75 | 7.86 | 13.62 | 12.81 | +81.2% |
| EBIT | $1.54B | $844.10M | $1.06B | $1.78B | $1.52B | +82.3% |
| EBITDA | $1.66B | $967.30M | $1.20B | $1.92B | $1.66B | +71.9% |
| Basic shares | 102.80M | 104.00M | 102.90M | 103.60M | 105.10M | -1.2% |
| Diluted shares | 106.00M | 107.70M | 107.50M | 107.20M | 108.60M | -1.6% |
| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | YoY |
|---|---|---|---|---|---|---|
| Cash & equivalents | $2.46B | $2.96B | $3.12B | $2.51B | $2.00B | -17.1% |
| Cash & short-term investments | $7.99B | $8.75B | $8.61B | $8.44B | $7.47B | -8.7% |
| Accounts receivable | $6.57B | $5.73B | $5.74B | $5.69B | $5.61B | +14.6% |
| Inventory | $3.08B | $3.10B | $3.20B | $3.25B | $3.21B | -0.6% |
| Total current assets | $18.45B | $18.21B | $18.02B | $17.98B | $16.86B | +1.3% |
| Property, plant & equipment | $5.46B | $5.27B | $5.12B | $5.00B | $4.84B | +3.7% |
| Goodwill & intangibles | $1.31B | $1.29B | $1.26B | $1.38B | $1.35B | +1.8% |
| Total assets | $41.73B | $40.87B | $40.56B | $40.17B | $38.22B | +2.1% |
| Total current liabilities | $5.53B | $5.11B | $4.37B | $4.43B | $3.67B | +8.3% |
| Long-term debt | $1.99B | $1.99B | $1.99B | $1.99B | $1.99B | +0.0% |
| Total debt | $2.71B | $2.71B | $2.71B | $2.71B | $2.71B | +0.0% |
| Total liabilities | $10.02B | $9.45B | $9.30B | $9.21B | $8.28B | +6.1% |
| Retained earnings | $37.62B | $36.42B | $35.80B | $35.05B | $33.68B | +3.3% |
| Shareholder equity | $31.71B | $31.42B | $31.26B | $30.96B | $29.94B | +0.9% |
| Working capital | $12.92B | $13.10B | $13.65B | $13.56B | $13.19B | -1.4% |
| Net tangible assets | $30.40B | $30.14B | $30.00B | $29.58B | $28.59B | +0.9% |
| Shares issued | 103.14M | 139.72M | 139.42M | 138.02M | 138.02M | -26.2% |
| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | YoY |
|---|---|---|---|---|---|---|
| Net income | $1.30B | $727.20M | $844.60M | $1.46B | $1.39B | +78.3% |
| Depreciation & amortisation | $123.70M | $123.20M | $145.00M | $136.70M | $135.10M | +0.4% |
| Stock-based compensation | $243.00M | $257.40M | $249.30M | $237.00M | $251.70M | -5.6% |
| Change in working capital | -$649.20M | $36.50M | $5.90M | $625.00M | -$227.90M | -1,878.6% |
| Operating cash flow | $813.00M | $1.08B | $1.17B | $1.62B | $1.14B | -24.6% |
| Capital expenditure | -$291.20M | -$279.50M | -$290.70M | -$244.70M | -$406.80M | -4.2% |
| Investing cash flow | -$92.70M | -$428.90M | $220.30M | -$402.90M | -$1.09B | +78.4% |
| Share buybacks | -$1.18B | -$867.50M | -$1.19B | -$667.00M | -$1.07B | -35.7% |
| Dividends paid | -$96.80M | -$97.80M | -$92.70M | -$91.20M | -$92.60M | +1.0% |
| Financing cash flow | -$1.22B | -$802.20M | -$780.10M | -$717.90M | -$1.13B | -52.7% |
| Free cash flow | $521.80M | $799.40M | $880.00M | $1.37B | $737.60M | -34.7% |
| End cash position | $2.47B | $2.97B | $3.12B | $2.51B | $2.02B | -17.0% |
Options analytics
Put / call volume
0.22
Call-heavy session
Put / call open interest
0.90
Positioning, not flow
Max pain
735.00
-0.5% from spot
ATM implied vol
44.6%
Nearest strike to spot
Skew (10% OTM)
-17.4%
Calls bid over puts
Call volume
341
Contracts, this expiry
Put volume
74
Contracts, this expiry
Heaviest call OI
735.00
112 contracts
Heaviest put OI
730.00
78 contracts
Max pain is the strike at which the largest dollar value of open contracts expires worthless. It describes current positioning; it is not a forecast and it moves as open interest changes.
Put/call ratios, max pain, implied volatility skew and where open interest is concentrated.
Earnings
Reported vs expected · EPS
| Quarter | Est. | Actual | Surprise |
|---|---|---|---|
| Jun 2026 | 10.21 | 14.29 | +40.0% |
| Mar 2026 | 8.90 | 9.47 | +6.4% |
| Dec 2025 | 10.75 | 11.44 | +6.4% |
| Sep 2025 | 9.64 | 11.83 | +22.7% |
Forward consensus
| Period | EPS | Analysts | Revenue | Growth |
|---|---|---|---|---|
| Current quarter | 16.00 | 22 | $4.54B | +21.0% |
| Next quarter | 16.34 | 21 | $4.74B | +22.0% |
| Current year | 55.30 | 27 | $17.08B | +19.1% |
| Next year | 50.63 | 9 | $18.48B | +8.2% |
Analyst targets & ownership
Mean target$855.12
High target$1,030.00
Low target$730.00
Implied upside16.50%
Analyst count26
ConsensusBUY
Strong buy / Buy4 / 14
Hold8
Sell / Strong sell0 / 1
Held by insiders2.08%
Held by institutions93.54%
Institutions holding1.91K
Price targets, consensus spread, insider and institutional ownership.
Moving averages & technicals
SMA 10
758.21
-3.19% from price
SMA 20
774.17
-4.58% from price
SMA 50
787.70
-6.22% from price
SMA 100
713.49
+2.87% from price
SMA 200
735.89
+0.38% from price
EMA 12
757.16
-3.06% from price
EMA 26
771.86
-4.91% from price
EMA 50
766.09
-4.19% from price
RSI (14)
38.2
Neutral
MACD (12,26,9)
-14.70
Hist -7.23
ATR (14)
21.14
2.86% of price
Realised vol 30D
28.2%
Annualised
Bollinger upper
825.27
20, 2σ
Bollinger lower
723.07
20, 2σ
50 / 200 cross
Golden
787.70 vs 735.89
Trend bias
Above 200
+0.38%
Options chain
Calls
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Puts
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Every listed expiry, both sides of the book, with volume, open interest and implied volatility.
Risk profile
Beta vs SPY
0.47
Less volatile than market
Correlation to SPY
0.19
Largely independent
Realised vol 30D
28.2%
Annualised
Market vol 1Y
13.0%
SPY, annualised
Max drawdown 1Y
-26.1%
Peak to trough
Max drawdown 5Y
-59.8%
Peak to trough
ATR 14
21.14
2.86% of price
Beta (reported)
0.15
5Y monthly, from filing
Short interest
Shares short
2.53M
Prior 2.40M
Change vs prior
+5.4%
Shorts adding
% of float
2.60%
Normal
% of shares out
2.45%
Against total outstanding
Days to cover
4.0
Liquid
Float
95.85M
Freely tradeable shares
Exchanges publish short interest twice a month with a settlement lag, so this is roughly two weeks behind. Days to cover divides shares short by average daily volume — it estimates how long covering would take, not whether it will happen.
Rating changes
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Oct 6, 26 | JP Morgan | MAINTAINED | Overweight | Overweight |
| Oct 1, 26 | Jefferies | MAINTAINED | Buy | Buy |
| Oct 1, 26 | Argus Research | UPGRADE | Hold | Buy |
| Sep 29, 26 | RBC Capital | MAINTAINED | Sector Perform | Sector Perform |
| Sep 10, 26 | HSBC | MAINTAINED | Buy | Buy |
| Aug 17, 26 | Leerink Partners | MAINTAINED | Market Perform | Market Perform |
| Aug 3, 26 | Citigroup | MAINTAINED | Neutral | Neutral |
| Aug 3, 26 | Guggenheim | MAINTAINED | Buy | Buy |
| Jul 31, 26 | RBC Capital | MAINTAINED | Sector Perform | Sector Perform |
| Jul 31, 26 | Morgan Stanley | MAINTAINED | Equal-Weight | Equal-Weight |
| Jul 31, 26 | Cantor Fitzgerald | MAINTAINED | Overweight | Overweight |
| Jul 31, 26 | Wells Fargo | MAINTAINED | Equal-Weight | Equal-Weight |
Dividends & splits
Forward rate$3.76 / yr
Forward yield0.52%
5-year avg yield—
Payout ratio9.00%
Ex-dividend dateAug 18, 2026
Next pay dateAug 31, 2026
Last split—
Split date—
SEC filings
Corporate Changes & Voting Matters
8-K · 2026-10-06
Corporate Changes & Voting Matters
8-K · 2026-09-30
Annual Report of Proxy Voting Record of Registered Management Investment Companies filed on Form N-PX
N-PX · 2026-08-20
Corporate Changes & Voting Matters
8-K · 2026-07-30
Corporate Changes & Voting Matters
8-K · 2026-07-06
Corporate Changes & Voting Matters
8-K · 2026-06-17
Periodic Financial Reports
10-Q · 2026-04-29
Annual Report to Shareholders
ARS · 2026-04-24
Headlines
Expanded Sanofi Alliance And New Pipeline Data Could Be A Game Changer For Regeneron (REGN)
Simply Wall St. · 5h ago
Health Care Roundup: Market Talk
The Wall Street Journal · 6h ago
Regeneron Showcases Advances in Care Across Several Cancers and Cancer-associated Complications at ESMO 2026
GlobeNewswire · 16h ago
JPMorgan Adjusts PT on Regeneron Pharmaceuticals to $950 From $900, Keeps Overweight Rating
MT Newswires · 16h ago
Vertex (VRTX) or Regeneron (REGN)? Two Biotech Moats, Two Very Different Bets
Insider Monkey · 4d ago
Stocktwits Biotech Dealmaker — Novartis, Sanofi And Novo Sign Week’s Biggest Deals
Stocktwits · 4d ago
An $8 Billion Reason Why Regeneron Stock Is in Focus
Barchart · 4d ago
This week in charts: Kodiak’s big comeback and Hengrui’s dealmaking
BioPharma Dive · 4d ago
PRIVATE STRATEGY · BY QUALIFICATION
The same data. A different seat.
The research you are reading is the input layer for a discretionary options program we run for a small number of qualified investors. Minimum $1,000,000.